article thumbnail

STAT+: Life sciences deals on track to hit lowest point since 2017

STAT

If dealmaking remains consistent for the rest of the year, it would put this year on par with the number of deals made in 2017. For comparison, there were roughly 2,122 financing deals made last year. Continue to STAT+ to read the full story…

141
141
article thumbnail

Preserving Patient Access to Compounded Medications Act of 2017

Pharmacy Times

The act would have permitted health care facilities to stock up on compounded medications without forcing the supplying 503A pharmacies to register as outsourcing facilities.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Rite Aid Addresses Cyberattack: 2.2 Million Customers’ Data Breached

Drug Topics

The retail pharmacy chain issued an alert to its customers that purchasing data from 2017 to 2018 may have been breached by a third party.

209
209
article thumbnail

FDA: Fasenra Approved As Add-On Maintenance Therapy for Severe Pediatric Asthma

Drug Topics

Fasenra was initially approved in 2017 as an add on maintenance therapy in patients aged 12 years and older.

FDA 154
article thumbnail

STAT+: Pharmalittle: Life sciences deals on track to hit lowest point since 2017; EU regulators order Illumina to divest Grail

STAT

Good morning, everyone, and welcome to another busy day. We are scrambling, in fact, to update our to-do list, schedule online calls, and sort out deadlines. To cope, we are quaffing several cups of stimulation, of course. Our choice today is maple bourbon. Meanwhile, here is the latest selection of interesting items for you to peruse.

102
102
article thumbnail

Updated USPSTF Guidelines Show Benefits of Screening for Obstructive Sleep Apnea Do Not Outweigh Harms

Pharmacy Times

The decision is updated from a 2017 recommendation to screen people for obstructive sleep apnea, which can lead to daytime sleepiness and other adverse outcomes.

139
139
article thumbnail

PTC wins FDA approval for first brain-delivered gene therapy Kebilidi

Fierce Pharma

The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy has already been approved to treat AADC deficiency in Europe and the U.K., among other countries, where it's branded as Upstaza.

FDA 131